Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.

Elsa Dalmau, Alejandra Armengol-Alonso, Montserrat Muñoz, Miguel Ángel Seguí-Palmer

Journal: Breast (Edinburgh, Scotland) 2015;23(6):710-20

PMID: 25311296

Full Text on Elsevier Science View on PubMed

Abstract

The natural history of HR+ breast cancer tends to be different from hormone receptor-negative disease in terms of time to recurrence, site of recurrence and overall aggressiveness of the disease. The developmental strategies of hormone therapy for the treatment of breast cancer have led to the classes of selective estrogen receptor modulators, selective estrogen receptor downregulators, and aromatase inhibitors. These therapeutic options have improved breast cancer outcomes in the metastatic setting, thereby delaying the need for chemotherapy. However, a subset of hormone receptor-positive breast cancers do not benefit from endocrine therapy (intrinsic resistance), and all HR+ metastatic breast cancers ultimately develop resistance to hormonal therapies (acquired resistance). Considering the multiple pathways involved in the HR network, targeting other components of pathologically activated intracellular signaling in breast cancer may prove to be a new direction in clinical research. This review focuses on current and emerging treatments for HR+ metastatic breast cancer.

Address: Oncology Department, Parc Taulí Sabadell, Hospital Universitari, Parc Taulí, 1, 08208 Sabadell, Barcelona, Spain. Electronic address: [email protected].; Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga #15, CP 14000 México City, Mexico. Electronic address: [email protected].; Oncology Department, Hospital Clinic i Provincial, IDIBAPS, C/Villarroel, 170, 08036 Barcelona, Spain. Electronic address: [email protected].; Oncology Department, Parc Taulí Sabadell, Hospital Universitari, Parc Taulí, 1, 08208 Sabadell, Barcelona, Spain. Electronic address: [email protected].

DOI: 10.1016/j.breast.2014.09.006

Link outs

Free resources

Medical:

https://medlineplus.gov/breastcancer.html

Other Literature Sources:

https://scite.ai/reports/25311296

Subscription / membership required

Full Text Sources:

MeSH Terms: Anastrozole, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Breast Neoplasms, Drug Resistance, Neoplasm, Estradiol, Female, Fulvestrant, Humans, Neoplasm Metastasis, Nitriles, Receptors, Estrogen, Receptors, Progesterone, Selective Estrogen Receptor Modulators, Tamoxifen, Triazoles